OpZira™ appoints Scott Thielman, PhD, PE, as VP of Product Development to advance technologies aimed at earlier detection and monitoring of ocular disease (DryAMD). The update is operational and supportive but not indicative of near-term financial impact, so likely limited stock movement.
OpZira™ appoints Scott Thielman, PhD, PE, as VP of Product Development to advance technologies aimed at earlier detection and monitoring of ocular disease (DryAMD). The update is operational and supportive but not indicative of near-term financial impact, so likely limited stock movement.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.12
